Skip to main content
. 2014 May 3;210(8):1260–1269. doi: 10.1093/infdis/jiu244

Table 2.

Estimated Proportion of Wild-Type (wt; I221) Neuraminidase (NA) in Clinical Specimens, Compared With the Oseltamivir Phenotype for the Corresponding Virus Isolate

Days After Clinical Onset Type of Specimen NA Gene Level, Copies/mL Specimena wt (I221) NA Proportion, % Virus Recovered Oseltamivir Phenotype
12 NPA 280 000 100 B/Lyon/CHU/12.88/2011 NI (wt)
18 NPA 4 760 000 100 B/Lyon/CHU/12.1127/2011 NI (wt)
22 NPA 6 090 000 100 B/Lyon/CHU/13.584/2011 NI (wt)
28 NPA 217 000 100 B/Lyon/CHU/14.411/2011 NI (wt)
30 NPA 770 000 100 B/Lyon/CHU/14.767/2011 NI (wt)
34 NPA 4 172 000 1 B/Lyon/CHU/15.216/2011 HRI (221L)
35 NPA 6300 100 B/Lyon/CHU/15.489/2011 NI (wt)
37 NPA 3 920 000 11 B/Lyon/CHU/15.731/2011 NI (wt)
40 N 259 000 5 B/Lyon/CHU/16.167/2011 HRI (221L)
42 BAL 4 018 000 0.70 B/Lyon/CHU/16.432/2011 HRI (221L)

Quantification of the wt or mutant NA was performed using real-time reverse-transcription quantitative polymerase chain reaction, using specific probes for I221 (wt) or 221L (mutant) NA, as described in Materials and Methods.

Abbreviations: BAL, bronchoalveolar lavage; N, nasal swab; NPA, nasopharyngeal aspirate.

a Data total no. of I221 (wt) and 221L (mutant) NA gene copies.